Liu Bin, Wu Zhenjie, Mo Hao, He Juliang, Lin Xiang, Guan Jian, Wei Changyuan, Yuan Zhenchao
Department of Bone and Soft Tissue Neurosurgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi, People's Republic of China,
Department of Breast Tumor Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi, People's Republic of China,
Cancer Manag Res. 2018 Nov 14;10:5685-5689. doi: 10.2147/CMAR.S176743. eCollection 2018.
The objective of the study was to assess the safety and efficacy of microwave ablation (MWA) for breast cancer thoracic metastasis.
Twelve patients in our institution with a single lesion of breast cancer thoracic metastases received MWA and invasive spine surgery from August 2014 to November 2016. MWA was executed using the MWA system (2,450 MHz) at 40 W or 50 W with thermometers to control the ablation end points. The pathology of thoracic metastases was confirmed through intraoperative biopsy before ablation. The postoperative complications were recorded. The patients were followed up at 1, 3 and 6 months with contrast-enhanced computed tomography and magnetic resonance imaging to monitor for tumor recurrence.
The average duration of follow-up for breast cancer thoracic metastases patients (mean age 52.7±8.4 years) was 10.2 months. The rate of postoperative main complications was 8.3% (1/12). The recurrence rate was 16.6% (2/12) as confirmed by persistent enhancement.
MWA may be used as the adjuvant treatment for thoracic metastases of breast cancer. Results showed that few significant complications and less local recurrence occurred during the follow-up stage. Future research should aim at discovering more about the time controls for microwave-tissue interaction and treatment parameters before widespread use.
本研究的目的是评估微波消融（MWA）治疗乳腺癌胸壁转移的安全性和有效性。
2014年8月至2016年11月，我院12例单发乳腺癌胸壁转移患者接受了MWA和脊柱侵入性手术。使用MWA系统（2450 MHz）以40 W或50 W功率进行MWA，并使用温度计控制消融终点。在消融前通过术中活检确认胸壁转移灶的病理情况。记录术后并发症。在术后1、3和6个月进行增强计算机断层扫描和磁共振成像随访，以监测肿瘤复发情况。
乳腺癌胸壁转移患者（平均年龄52.7±8.4岁）的平均随访时间为10.2个月。术后主要并发症发生率为8.3%（1/12）。经持续强化证实，复发率为16.6%（2/12）。
MWA可作为乳腺癌胸壁转移的辅助治疗方法。结果显示，随访期间严重并发症较少，局部复发率较低。在广泛应用之前，未来的研究应致力于进一步了解微波与组织相互作用的时间控制和治疗参数。
